Makary Would Have Wide Leeway To Make GLP-1 Compounding Decisions As US FDA Commissioner

 
• By Sarah Karlin-Smith

FDA Commissioner nominee Martin Makary can comply with US ethics laws while weighing in on the contentious GLP-1 compounding debate, despite recently exiting a company that connects patients with compounded semaglutide and an ophthalmology compounding business.

magnifying glass over GLP-1 written on scrap of paper. other paper scraps read "obesity," "semaglutide" "weight loss"
The FDA Commissioner nominee can play an active role in GLP-1 policy despite past conflicts of interest. (Shutterstock)

More from US FDA

More from Geography